What the FDA labels say about taking them together
Riociguat and theophylline
Riociguat's FDA label of August 13, 2026 names theophylline in its contraindications section; the theophylline label PlainMeds reads does not name riociguat. The riociguat label: “Concomitant administration of Adempas with specific PDE-5 inhibitors or nonspecific PDE-5 inhibitors is contraindicated.”
Check it at the source: the riociguat FDA label on DailyMed (effective August 13, 2026, Bayer HealthCare Pharmaceuticals Inc.); the theophylline FDA label on DailyMed (effective March 10, 2026, Strides Pharma Science Limited).
What does the riociguat label say about theophylline?
Riociguat label, contraindicationsConcomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )].
Riociguat label, drug interactionsPDE Inhibitors: Co-administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or theophylline), is contraindicated because of hypotension.
Source: FDA drug label (Adempas), Bayer HealthCare Pharmaceuticals Inc., effective August 13, 2026 (SPL set 7b57509a-3d5d-41d4-8fed-1471e26372a3), via openFDA; the full label on DailyMed
What does the theophylline label say about riociguat?
Theophylline's label (effective March 10, 2026) does not name riociguat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Theophylline), Strides Pharma Science Limited, effective March 10, 2026 (SPL set b7a90ccf-9c32-40cc-9008-7e55b3da4dfd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Riociguat | Theophylline | |
|---|---|---|
| Labeled for | Pulmonary arterial hypertension | Asthma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.330 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once